# A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

> **NCT04562116** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 17 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Nemolizumab
- **DRUG:** CYP 450 Substrates

## Key facts

- **NCT ID:** NCT04562116
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-08
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-06-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562116, "A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04562116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*